CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2016—Biocept launched its CLIA-validated PD-L1 protein expression test, which uses Biocept’s proprietary, patented Target Selector platform with circulating tumor cells from a patient’s blood sample and can be used to detect and monitor PD-L1 protein expression throughout the course of a patient’s cancer therapy. The test was developed by Biocept’s scientists in collaboration with David Rimm, MD, PhD, professor of pathology and medicine at Yale University School of Medicine and a scientific advisor to the company.
Biocept, 858-320-8200